TY - JOUR T1 - Atorvastatin was at least as effective as PTCA for reducing ischaemic events in patients with stable coronary artery disease JF - Evidence Based Medicine JO - Evid Based Med SP - 14 LP - 14 DO - 10.1136/ebm.5.1.14 VL - 5 IS - 1 A2 - , Y1 - 2000/01/01 UR - http://ebm.bmj.com/content/5/1/14.abstract N2 - (1999) N Engl J Med 341, 70. Pitt B, Waters D, Brown WV, et al. for the Atorvastatin versus Revascularization Treatment Investigators.. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.. Jul 8;. :. –6.OpenUrlCrossRefPubMedWeb of Science
 
 QUESTION: In patients with stable coronary artery disease (CAD), is atorvastatin as effective as percutaneous transluminal coronary angioplasty (PTCA) plus usual care for reducing ischaemic events? Randomised, blinded (outcome assessors),* controlled trial with 18 months follow-up. 37 clinical centres in North America and Europe. 341 patients (mean age 59 y, 85% men, 95% white) recommended for PTCA who had stable CAD and asymptomatic or Canadian Cardiovascular Society class I or II angina, low-density lipoprotein (LDL) cholesterol level ≥3.0 mmol/l (115 mg/dl), triglyceride level ≤5.6 mmol/l (500 mg/dl), and stenosis ≥50% in ≥1 coronary artery. Exclusion criteria were left main CAD, triple-vessel disease, ejection fraction <40%, or recent unstable angina or myocardial infarction (MI). Follow-up was 100%. 164 patients were allocated to atorvastatin, 80 mg/day, and were required to stop other lipid-lowering treatments. 177 patients were allocated to PTCA and usual … ER -